Listen to members of the writing group for the new AHA statement on the clinical management of stable coronary artery disease in patients with T2D. Dr. Suzanne Arnold, Chair, and fellow writing group members, Dr. Prakash Deedwania and Dr. Mikhail Kosiborod will review highlights from the statement, including recent clinical trials which uncovered several new drugs that not only reduce glucose, but also improve cardiovascular and renal outcomes.